Relevant data are included as Supporting Information files.

Introduction {#sec001}
============

Conceptualization of psychopathology is at a crossroads, garnering heightened interest among researchers and clinicians alike. The substantive dialogue of the past decade regarding the classification of mental illness contributed importantly to revisions for DSM-5 \[[@pone.0115820.ref001],[@pone.0115820.ref002]\]. Also receiving consideration were alternatives to symptom-based approaches of classification, giving rise to the Research Domains Criteria (RDoC) initiative \[[@pone.0115820.ref003]\], which challenges a number of conventions in psychiatric research. This initiative proposes moving beyond traditional diagnostic categories to conduct research on a range of psychopathology with similar features, such as anxiety and depressive disorders. Another emphasis of the RDoC initiative is on biological measures. Although research to date did not warrant greater inclusion of biological criteria in DSM-5, gains have been made in identifying promising brain and genetic contributions to anxiety and depressive pathology. The field of neuroimaging genetics is uniquely positioned to inform ongoing developments regarding psychiatric diagnosis.

The serotonin system has been strongly implicated in affective psychopathology and associated brain areas, as indicated by research at the non-human animal level \[[@pone.0115820.ref004]\] and by genetic association studies and neuroimaging studies in humans and non-human primates \[[@pone.0115820.ref005]\]. Medications that affect serotonin levels in the brain by inhibiting the reuptake of serotonin into the pre-synaptic terminal are first-line treatments for clinical anxiety and depression. Serotonin levels are also affected by the serotonin transporter gene, *SLC6A4*, on chromosome 17q11.1-q12, which encodes 5-HTT protein. The transcriptional activity of this gene is modulated by a variable number of tandem repeats for the linked polymorphic region (5-HTTLPR), most commonly occurring as 14 repeats for the short (S) allele or as 16 repeats for the long (L) allele. A second variant in the 5-HTT promoter region, an A to G single nucleotide polymorphism (rs25531), greatly reduces mRNA expression in the L~G~ compared to L~A~ carriers, rendering the L~G~ variant functionally similar to the S allele \[[@pone.0115820.ref006]\]. S/L~G~ allele carriers compared with L~A~ homozygotes have largely reduced serotonin transporter expression, fewer 5-HT~1A~ receptors, and increased adrenocorticotropic hormone responses to stress \[[@pone.0115820.ref007]\]. However, the consequences for serotonin reuptake and extracellular serotonin levels remain controversial \[[@pone.0115820.ref008],[@pone.0115820.ref009]\].

In numerous studies of non-psychiatric groups, which have only rarely used the triallelic classification, S carriers have shown greater amygdala activity to emotional stimuli than individuals with two L alleles, although the effect size is small \[[@pone.0115820.ref010]\]. The few triallelic studies with patient samples thus far show mixed results \[[@pone.0115820.ref010],[@pone.0115820.ref011],[@pone.0115820.ref012],[@pone.0115820.ref013]\]. Early notions that the S allele promote anxiety have not always been supported, with amygdala responses often normative in S carriers and diminished in individuals with two L alleles \[[@pone.0115820.ref014],[@pone.0115820.ref015]\]. Regardless, greater amygdala activation in S/L~G~ carriers than L~A~ homozygotes is consistent with studies reporting 5-HTTLPR differences in attention biases to threat, fear-potentiated startle, and neuroendocrine responsivity \[[@pone.0115820.ref005],[@pone.0115820.ref016]\] which predict exaggerated reactivity for S/L~G~ carriers in our experimental context.

The critical role of the serotonin system in affective disorders makes the need for research in patient samples paramount. Patient studies that also assess 5-HTTLPR genetic effects are obscured by methodological complications such as: including medicated patients (mostly with serotonergic drugs) \[[@pone.0115820.ref013],[@pone.0115820.ref017],[@pone.0115820.ref018]\], not including healthy comparison subjects \[[@pone.0115820.ref017],[@pone.0115820.ref018],[@pone.0115820.ref019]\], and not including the triallelic genotype classification \[[@pone.0115820.ref018],[@pone.0115820.ref019]\]. A notable exception investigating unmedicated MDD patients using the triallelic assay found evidence of low gene expression associated with greater amygdala activation to aversive pictures in depressed patients compared with controls \[[@pone.0115820.ref012]\]. Expanding on this work in a related sample, the present study addresses the impact of triallelic 5-HTTLPR genotype on affective neurocircuitry in unmedicated anxious patients across the related and commonly comorbid conditions of generalized anxiety disorder (GAD), social anxiety disorder (SAD), and major depressive disorder (MDD). GAD is characterized by chronic worry that is difficult to control about a number of different topics. MDD diagnosis includes consistent depressed mood and/or diminished interest or pleasure in normal activities and an SAD diagnosis reflects clinical levels of anxiety concerning social and evaluative situations. Clinically, all three disorders typically present with symptoms in common such as negative affect/distress, sleep problems, and concentration problems. Anticipation and response to emotional information are expected to be discontinuous with healthy participant data in patients and are assessed here using our task designed to activate neural circuits in healthy controls \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022]\] as well as patients \[[@pone.0115820.ref023]\] including those brain regions of paramount interest to the present investigation, the amygdala and anterior insular cortex, as explained below.

The amygdala and insula are both broadly implicated in social-emotional processing \[[@pone.0115820.ref024],[@pone.0115820.ref025]\], in the anticipation of aversive events \[[@pone.0115820.ref026]\], and in group effects associated with affective disorders compared with healthy populations \[[@pone.0115820.ref024]\]. There is a strong non-human animal literature on the role of the amygdala in fear learning and memory \[[@pone.0115820.ref027]\] which is thought to parallel development of affective disorders in humans \[[@pone.0115820.ref028],[@pone.0115820.ref029],[@pone.0115820.ref030]\]. The anterior portion of the insular cortex is particularly linked to theoretical work on anxiety \[[@pone.0115820.ref020],[@pone.0115820.ref031],[@pone.0115820.ref032]\], especially as it involves sensory information \[[@pone.0115820.ref025]\] with the integration of salient or emotional material \[[@pone.0115820.ref033],[@pone.0115820.ref034],[@pone.0115820.ref035]\].

Hyperreponsivity of the amygdala and anterior insula are the two consistent functional findings for SAD \[[@pone.0115820.ref024]\]. Those same two areas are among the most frequently showing effects in GAD \[[@pone.0115820.ref023],[@pone.0115820.ref036],[@pone.0115820.ref037]\], as well. A recent meta-analysis found that the amygdala and anterior insula are also implicated in MDD pathophysiology \[[@pone.0115820.ref038]\]. Some studies in all three disorders have failed to find evidence of amygdala and/or insula hyperactivity \[[@pone.0115820.ref023],[@pone.0115820.ref039],[@pone.0115820.ref040],[@pone.0115820.ref041],[@pone.0115820.ref042]\], which may be partially explained by within-group differences including 5HTTLPR genotype. The present study expands the investigation across these disorders using an anticipatory anxiety paradigm designed to specifically tap brain circuitry associated with anxiety and depression and previously shown to activate the amygdala and anterior insula \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022],[@pone.0115820.ref043]\]. The notion of anticipation is essential to describe anxious states and is fundamental to descriptions of anxious pathology \[[@pone.0115820.ref044]\]. This study tested whether variations in affective neural responses found in prior studies of GAD, SAD, and MDD are influenced by 5-HTTLPR genotype across those diagnostic categories. We also sought to extend findings from diverse behavioral and biological assessments of 5-HTTLPR genotype in healthy participants to investigations of the anticipation of emotional information, given our previous fMRI findings in healthy and patient populations \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022],[@pone.0115820.ref023],[@pone.0115820.ref045]\].

Materials and Methods {#sec002}
=====================

Participants {#sec003}
------------

The study was authorized by the University of Wisconsin institutional review board and after complete description of the study at the outset of the first experimental session, all participants gave written informed consent before participating and no minors were included in the research. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All 89 participants were administered the Structured Clinical Interview for DSM-IV by DJO and postdoctoral/graduate---level clinicians, with diagnostic discrepancies resolved by consensus of those clinicians and JBN after viewing videotaped interviews. Healthy comparison subjects (*n* = 39) had no current or past neurological or psychiatric disorders and reported no family history of mental illness. Patients (*n* = 50) included 24 who met criteria for GAD but no other current Axis I disorder (15 of those also had no other past Axis I diagnosis, 7 with past MDD), 9 who met criteria for GAD and depression but not SAD (7 MDD, 1 dysthymia, 1 MDD and dysthymia), 7 who met criteria for GAD and SAD but not depression (2 with past MDD, 1 with past MDD and dysthymia), and 10 who met criteria for all three. The only other observed diagnoses in the patient group were for substance use (9 past substance dependence, 1 current substance abuse, 1 past alcohol abuse). Participants were excluded if they reported a history of psychosis or bipolar disorder. No participant was taking psychiatric medications during the study (for patients with medication history, time since last use exceeded 3 half-lives). [Table 1](#pone.0115820.t001){ref-type="table"} lists demographic and genotyping information, and [Table 2](#pone.0115820.t002){ref-type="table"} provides scores on the Hamilton Rating Scales of Anxiety (Ham-A) \[[@pone.0115820.ref046]\] and Depression (Ham-D) \[[@pone.0115820.ref047]\], the Penn State Worry Questionnaire (PSWQ) \[[@pone.0115820.ref048]\], and the Intolerance of Uncertainty Scale (IUS) \[[@pone.0115820.ref049]\].

10.1371/journal.pone.0115820.t001

###### Demographic and genotypic information for patients and healthy comparison subjects.

![](pone.0115820.t001){#pone.0115820.t001g}

                                                 Healthy Comparison Subjects (*n* = 39)   Patients (*n* = 50)
  ---------------------------------------------- ---------------------------------------- ---------------------
  Age, Mean (SD)                                 24.64 (6.88)                             27.38 (10.07)
  Sex, *n* (%)                                   21 female (53.8)                         38 female (76.0)
  Ethnic Background, *n*                                                                  
  Europe                                         30                                       41
  Africa                                         2                                        3
  Far East Asia                                  6                                        5
  Undeclared                                     1                                        1
  5-HTTLPR Genotype, *n* (%)                                                              
  L~A~L~A~                                       9 (23)                                   14 (28)
  L~A~L~G~                                       2 (5)                                    3 (6)
  SL~A~                                          20 (51)                                  21 (42)
  SL~G~                                          1 (3)                                    3 (6)
  SS                                             7 (18)                                   9 (18)
  5-HTTLPR Genotype Grouping, *n* (%)                                                     
  S/L~G~ carriers (L~A~L~G~, SL~A~, SS, SL~G~)   30 (77)                                  36 (72)
  L~A~ homozygotes (L~A~L~A~)                    9 (23)                                   14 (28)

10.1371/journal.pone.0115820.t002

###### Symptom data for 5-HTTLPR groupings in patients and healthy comparison subjects.

![](pone.0115820.t002){#pone.0115820.t002g}

  5-HTTLPR Grouping                                          Ham-A          Ham-D           PSWQ            IUS
  ---------------------------------------------------------- -------------- --------------- --------------- ----------------
  [Healthy Comparison Subjects (*n* = 39), Mean (SD)]{.ul}                                                  
  S/L~G~                                                     1.51 (1.33)    2.22 (1.59)     33.53 (8.13)    60.27 (16.65)
  L~A~L~A~                                                   1.06 (0.84)    1.58 (1.57)     29.56 (7.60)    52.63 (10.10)
  [Patients (*n* = 50), Mean (SD)]{.ul}                                                                     
  S/L~G~                                                     17.55 (6.47)   26.06 (8.83)    61.71 (9.79)    105.14 (24.12)
  L~A~L~A~                                                   17.32 (6.14)   27.24 (11.29)   58.43 (10.35)   114.29 (22.61)

[Note:]{.ul} Ham-A = Hamilton Rating Scale for Anxiety. Ham-D = Hamilton Rating Scale for Depression. PSWQ = Penn State Worry Questionnaire. IUS = Intolerance of Uncertainty Scale.

Procedures {#sec004}
----------

As illustrated in [S1 Fig](#pone.0115820.s001){ref-type="supplementary-material"}., each trial began with an anticipatory cue presented for two seconds. An 'X' signified that an aversive picture would be presented, 'O' preceded neutral pictures, and '?' indicated that either could be presented (half were followed by aversive and half by neutral pictures). Participants were instructed about all cue-picture pairings prior to scanning. The cue was followed by an intertrial interval (ITI) of 2--8 s, then an aversive or neutral picture from the International Affective Picture System \[[@pone.0115820.ref050]\], another ITI of 5--9 s, then a 5 s rating period ([S1 Fig](#pone.0115820.s001){ref-type="supplementary-material"}.), and a final ITI of 1--5 s. Cues were white on a black background, and ITIs included a fixation cross. Trial order was pseudo-randomized, with the stipulation that no trial type (aversive, neutral, or uncertain) was presented more than twice in a row. Across four functional scan runs, there were 38 aversive pictures presented after 'X' cues, 38 neutral pictures presented after 'O' cues, and 19 of each after '?' cues, with all pictures presented only once. Aversive pictures were the most unpleasant and arousing in the picture set (e.g., mutilated bodies, attack scenes), based on published norms \[[@pone.0115820.ref050]\]. Pictures with neutral valence and low arousal ratings comprised the neutral pictures (e.g., household items).

**DNA**. DNA was extracted from buccal cells obtained from 10-ml rinse of commercial mouthwash, using the Gentra Puregene DNA purification system (Qiagen cat no. 158867). Genotypes for 5-HTTLPR (S and L alleles) and for rs25531 (L~A~ and L~G~ alleles) were determined using an established protocol \[[@pone.0115820.ref051]\]. Participants with L~G~ alleles were grouped with those expressing S alleles given evidence of nearly equivalent 5-HTT expression for these variants \[[@pone.0115820.ref006]\].

**MRI Data Acquisition, Processing, and Analysis**. Magnetic resonance images were acquired on a 3.0 Tesla scanner (GE Signa; Waukesha, WI) with a high-speed, whole-body gradient and whole-head transmit-receive coil (4 channel). Whole-brain high-resolution T1-weighted anatomical scans (axial acquisition, 3D, inversion-recovery spoiled gradient echo: FOV 240 mm, matrix 256x192, in-plane resolution 0.9 mm, 124 1.2-mm axial slices, 10° flip angle) were acquired contiguous with functional scans for aid in registration and normalization of functional data. Functional data (2D gradient echo \[GRE\] planar) consisted of 30 interleaved slices (slice thickness/gap: 4mm/1mm) acquired sagittally (TR = 2000 ms, TE = 30 ms, 90° flip angle) resulting in 64x64 matrix data with 240 mm FOV, and 3.75mm in-plane resolution. A Silent Vision system (Avotec, Inc., Jensen Beach, FL) displayed visual stimuli via stereoscopic goggles mounted on the head coil.

Processing of fMRI data was done using AFNI (<http://afni.nimh.nih.gov/afni/>) version 2.56a starting wtih slice-time correction, motion correction (6-parameter rigid body), fieldmap correction (GRE using sagittal acquisition; TE = 7 and 10 ms; TR = 700 ms) \[[@pone.0115820.ref052]\] then high pass temporal filtering (128s). Images from the four functional scan runs were aligned to the run closest in time to the high-resolution anatomical scan. To minimize the influence of magnetization equilibrium, the first three volumes of each scan were discarded. Event-related data were analyzed as percent change (vs. baseline) calculated for each subject. Events were modeled at the first-level using least-squares regression to fit the hemodynamic response function to a gamma variate for anticipation and response periods, separately \[[@pone.0115820.ref023]\], as well as the rating period (included in model but not analyzed here) all specified by aversive and neutral valence. Residuals from motion correction (6 directions) were included in the general linear model as regressors of no interest, and the baseline was modeled using a 5th order polynomial function. Each subject's T1 scan was AC/PC aligned and normalized to the MNI 152 brain using a 12-parameter affine transformation (\@auto_tlrc). Functional images were coregistered to the T1 in native space and in the same step normalized to MNI using the T1 derived algorithms. Alignment between functional and T1 as well as between warped data and MNI were visually inspected to confirm accurate registration.

Percent signal change values averaged over voxels in *a priori* regions of interest (ROI) for bilateral amygdala and anterior insula were extracted for each condition of interest (AFNI 3dmaskave; non-zero voxels). Both ROIs were defined using the Talairach Daemon atlas \[[@pone.0115820.ref053]\], with the additional specification for the anterior insula to only include voxels between y = 24 and y = -2. Study hypotheses were tested with diagnostic Group (patient, control) x Genotype (S/L~G~ carriers, L~A~ homozygotes) x Period (anticipation, picture) x Valence (aversive, neutral) ANOVAs for the amygdala and for the anterior insula ROI using SPSS (version 21). Analyses including the uncertain trials did not alter the hypothesized Group x Genotype findings and are not reported. No violations to assumptions were detected with Mauchly's test for assumption of sphericity (ANOVA) whereas degrees of freedom adjustments were made with significant findings from Levene's test for violations of homoscedasticity assumptions (*t*-tests). Pearson's correlations tested for associations between activity in each ROI and number of L~A~ alleles as follow up tests. Amygdala and insula associations with symptom measures (Ham-A, Ham-D, PSWQ, and IUS) were assessed in simultaneous regressions for relationships in patient data. For primary results, partial eta square for ANOVA and Hedges' unbiased measure of *g* \[[@pone.0115820.ref054]\] for *t*-tests are reported as effect size measures $\eta_{p}^{2}$ and *g*, respectively.

The above ROI-based analyses were supplemented with secondary voxelwise tests given evidence of functional and cellular heterogeneities across the amygdala \[[@pone.0115820.ref055],[@pone.0115820.ref056]\] and insula \[[@pone.0115820.ref025],[@pone.0115820.ref057]\] that may be more or less sensitive to our effects of interest. The voxelwise ANOVA testing the hypothesized Group x Gene interaction employed a tool for group analysis with unbalanced sample sizes (AFNI GroupAna). Voxelwise regressions were conducted for number of L~A~ alleles and for symptom measures. All voxelwise analyses were conducted beginning with uncorrected *p*\<.005 and thresholded to *p*\<0.05 corrected using small-volume (separate for bilateral amygdala and also for bilateral anterior insula) correction for multiple comparisons which resulted in a minimum cluster size of 240 mm^3^ for the amygdala and 504 mm^3^ for the anterior insula (AFNI AlphaSim). Figures display *p*\<.005 uncorrected images thresholded for cluster sizes corresponding to a corrected *p*\<.05.

Results {#sec005}
=======

Descriptives {#sec006}
------------

Fisher's exact test indicated no genotype differences by group, *p* = 0.634 ([Table 1](#pone.0115820.t001){ref-type="table"}). Across groups, L~A~ homozygotes were slightly younger (*M* = 21.91 vs. 27.67), *t*(76.73) = -3.769, *p* = 0.001, and less educated (*M* = 14.65 vs. 16.27 years) than S/L~G~ carriers, *t*(87) = -3.76, *p* = 0.001. Across genotype, patients did not differ from healthy comparison subjects on age, *t*(85.66) = 1.52, *p* = 0.132, or education, *t*(87) = -1.90, *p* = 0.061. Also, there was no interaction between genotype and patient status on age, *F*(1,85) = 0.02, *p* = 0.880 or education, *F*(1,85) = 0.53, *p* = 0.466. As expected, patients and healthy subjects differed on the Ham-A, Ham-D, PSWQ, and IUS (*p*s\<0.001), but there were no genotype differences on those instruments within each group (*p*s\>0.120). Participants in each group had allelic frequencies in Hardy-Weinberg equilibrium (*p*s\>0.600). Within the patient group, there were no differences by genotype in the number of comorbid disorders (L~A~: *M* = 0.93; S/L~G~: *M* = 0.92), *t*(48) = 0.05, *p* = 0.962. The ethnic composition of the sample was 5.6% African American, 12.4% Asian, and 79.8% Caucasian (1.1% ethnicity not reported). For primary results, each ethnic group was systematically evaluated as a potential outlier (see below) according to genotype and neural response. Neither group nor genotype varied systematically by ethnic identification (*p*s\>0.61). The patient group had a larger proportion of women than the control group, *Χ* ^2^(1) = 4.81, *p* = 0.028, but there was no gender disparity for genotype, *Χ* ^2^(1) = 0.81, *p* = 0.368.

Amygdala Effects {#sec007}
----------------

For the amygdala, a Valence main effect across anticipation and picture periods replicated previous findings of greater amygdala activation to aversive than neutral trials, *F*(1,85) = 10.09, *p* = 0.002 \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022]\], serving as a manipulation check. A Group x Genotype interaction for the amygdala, *F*(1,85) = 6.17, *p* = 0.015, $\eta_{p}^{2}$ = 0.07, revealed that S/L~G~-carrier patients had less amygdala activation than L~A~/L~A~ patients, *t*(48) = 3.58, *p* = 0.001, *g* = 0.81, and than S/L~G~-carrier comparison subjects, *t*(64) = -2.74, *p* = 0.008, *g* = 0.67 ([Fig. 1A](#pone.0115820.g001){ref-type="fig"}). Genotype differences previously reported in healthy samples \[[@pone.0115820.ref010]\] were not replicated within the comparison subjects, *t*(37) = -0.18, *p* = 0.859, *g* = 0.07, perhaps due to a failure to detect the small effect size estimated for this contrast \[[@pone.0115820.ref010]\]. In addition, patients showed an association between number of L~A~ alleles and amygdala activity, *r* = 0.39, *p* = 0.005, whereas the healthy comparison subjects did not, *r* = -0.04, *p* = 0.808, correlations that differed significantly from one another (Fisher r-to-z) *z* = -2.06, *p* = 0.047 ([Fig. 1B](#pone.0115820.g001){ref-type="fig"}). The findings were nearly identical for partial correlations controlling for age and years of education (patients *r* = 0.37, *p* = 0.010; controls *r* = -0.04, *p* = 0.815; *z* = -1.93, *p* = 0.027). These data were confirmed by voxelwise regressions at *p*\<0.05 (corrected) for the right amygdala and marginally for the left ([Fig. 1C](#pone.0115820.g001){ref-type="fig"}; [Table 2](#pone.0115820.t002){ref-type="table"}).

![5-HTTLPR genotype effects on amygdala activation differentiate patients and healthy comparison subjects.\
A) Patients with at least one S or L~G~ allele (*n* = 36) showed less amygdala activation than patients with two L~A~ alleles (*n* = 14) and than healthy comparison subjects with at least one S or L~G~ allele (*n* = 30). This Group x Genotype effect of 5-HTTLPR was observed in amygdala *a priori* regions of interest (inset) across aversive and neutral valences in anticipation of and response to affective pictures. B) A confirmatory finding in patients (n = 50) indicated a positive association between the number of L~A~ alleles of the serotonin transporter gene and bilateral activation in the amygdala *a priori* region of interest (inset). C) A voxelwise regression for patients indicated a positive association between L~A~ allele number and bilateral amygdala activation (inset) at *p*\<0.05, corrected. Y-axes display mean percent signal change averaged over displayed ROIs/clusters. Asterisks on the bar graph indicate significant differences at *p*\<0.05. Y-values on coronal images indicate Tailarach and Tournoux coordinates for the AFNI MNI-152 brain used for normalizing. Error bars are mean standard errors.](pone.0115820.g001){#pone.0115820.g001}

Across groups, amygdala effects for Genotype, *F*(1,85) = 4.93, *p*\<0.001, Period, *F*(1,85) = 3.36, *p*\<0.001, Valence, *F*(1,85) = 10.09, *p* = 0.002, and Period x Genotype, *F*(1,85) = 4.60, *p* = 0.035, were qualified by a three-way Genotype x Period x Valence interaction, *F*(1,85) = 12.49, *p* = 0.001. Posthoc analyses indicated a significant Genotype x Valence interaction for the picture period, *F*(1,85) = 6.03, *p* = 0.015, but not for the anticipation period, *F*(1,85) = 1.41, *p* = 0.110. L~A~/L~A~ homozygotes showed greater amygdala responses than S/L~G~ carriers to aversive pictures, *t*(87) = 3.94, *p*\<0.001, but not to neutral pictures, *t*(87) = 0.89, *p* = 0.376. There were no other effects for ROI-based analyses on the amygdala, and Group x Genotype findings for the amygdala did not attain the *p*\<0.05 (corrected) threshold of significance for voxelwise ANOVAs.

Anterior Insula Effects {#sec008}
-----------------------

Similar effects were observed for the anterior insula. The manipulation check testing the Valence main effect across anticipation and picture periods, *F*(1,85) = 13.93, *p*\<0.001, replicated previous findings for the anterior insula \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022]\]. The Group x Genotype interaction, *F*(1,85) = 6.18, *p* = 0.015, $\eta_{p}^{2}$ = 0.07, indicated that S/L~G~-carrier patients had less insula activation than L~A~/L~A~ patients, *t*(17.29) = 3.03, *p* = 0.007, *g* = 1.14 ([Fig. 2A](#pone.0115820.g002){ref-type="fig"}), whereas comparison subjects did not differ by genotype, *t*(28.38) = 0.23, *p* = 0.823, *g* = 0.06. Patients showed an association between number of L~A~ alleles and insula activity, *r* = 0.30, *p* = 0.034, whereas comparison subjects did not, *r* = -0.06, *p* = 0.733 ([Fig. 2B](#pone.0115820.g002){ref-type="fig"}), correlations that also yielded a one-tailed group difference, *z* = -1.67, *p* = 0.048. The findings were essentially identical for partial correlations controlling for age and years of education (patients *r* = 0.30, *p* = 0.042; controls *r* = -0.08, *p* = 0.644; *z* = -1.73, *p* = 0.039). Similar to the amygdala, correlations with the insula ROIs were confirmed by voxelwise regressions at *p*\<0.05 (corrected), which revealed bilateral anterior insula effects ([Fig. 2C](#pone.0115820.g002){ref-type="fig"}; [Table 2](#pone.0115820.t002){ref-type="table"}).

![5-HTTLPR genotype effects on anterior insula activation differentiate patients and healthy comparison subjects.\
A) Patients with at least one S or L~G~ allele (*n* = 36) showed less anterior insula activation than patients with two L~A~ alleles (*n* = 14). This Group x Genotype effect of 5-HTTLPR was observed in anterior insula *a priori* regions of interest (inset) across aversive and neutral valences in anticipation of and response to affective pictures. B) A confirmatory finding in patients (*n* = 50) indicated a positive association between the number of L~A~ alleles of the serotonin transporter gene and bilateral activation in anterior insula *a priori* region of interest (inset). C) A voxelwise regression for patients indicated a positive association between L~A~ allele number and bilateral anterior insula activation (inset) at *p*\<0.05, corrected. Y-axes display mean percent signal change averaged over displayed ROIs/clusters. Asterisks on the bar graph indicate significant differences at *p*\<0.05. Y-values on axial images indicate Tailarach and Tournoux coordinates for the AFNI MNI-152 brain used for normalizing. Error bars are mean standard errors.](pone.0115820.g002){#pone.0115820.g002}

Across groups, anterior insula effects for Genotype, *F*(1,85) = 7.25, *p* = 0.009, Period, *F*(1,85) = 18.81, *p*\<0.001, Valence, *F*(1,85) = 13.93, *p*\<0.001, and Period x Genotype, *F*(1,85) = 4.86, *p* = 0.030, were qualified by a three-way Genotype x Period x Valence interaction, *F*(1,85) = 8.49, *p* = 0.005. Similar to the amygdala, posthoc analyses indicated a significant Genotype x Valence interaction for the picture period, *F*(1,85) = 4.99, *p* = 0.028, but not for the anticipation period, *F*(1,85) = 0.32, *p* = 0.572. L~A~/L~A~ homozygotes showed greater insula responses than S/L~G~ carriers to aversive pictures, *t*(87) = 4.16, *p*\<0.001, but not to neutral pictures, *t*(87) = 1.35, *p* = 0.180. There were no other effects for the anterior insula, and Group x Genotype findings did not attain the *p*\<0.05 (corrected) threshold of significance for voxelwise ANOVAs.

Additional Regions {#sec009}
------------------

To test the specificity of similar findings observed for the amygdala and anterior insula, we conducted exploratory ROI analyses for other areas implicated in prior work on anticipating and responding to aversive pictures \[[@pone.0115820.ref020],[@pone.0115820.ref021],[@pone.0115820.ref022],[@pone.0115820.ref058]\]. The Group x Genotype effect was not observed for the pregenual anterior cingulate (pACC), anterior mid-cingulate (aMCC), or hippocampus for ROI-based analyses (all *p*s\>0.19) or for whole-brain voxelwise analyses at *p*\<0.05 (corrected) or *p*\<0.005 (uncorrected).

Symptom Correlates {#sec010}
------------------

Within the patient group, simultaneous regression analyses with the four symptom measures as predictors revealed that L~A~/L~A~ patients showed an association between activity in the *a priori* anterior insula ROIs and the IUS, s*ß* = 0.73, *p* = 0.029 (zero-order Pearson's correlation, *r* = 0.62, *p* = 0.018) ([Fig. 3A](#pone.0115820.g003){ref-type="fig"}). The anterior insula association with the IUS was also present for patients when collapsing across 5-HTTLPR status, s*ß* = 0.37, *p* = 0.024, but not for patients who were S/L~G~ carriers, s*ß* = 0.11, *p* = 0.584. The insula/IUS correlation was also significant as a partial correlation controlling for the other scales (PSWQ, HamA, HamD) in the full patient group (*r* = 0.33, *p* = 0.024) and in the L~A~/L~A~ group (*r* = 0.65, *p* = 0.029), but not in the S/L~G~ carriers (*r* = 0.10, *p* = 0.584). A voxelwise regression at *p*\<0.05 (corrected) revealed the same association with the IUS in bilateral insula for the L~A~/L~A~ subgroup of patients, as well as for the patients overall ([Fig. 3B](#pone.0115820.g003){ref-type="fig"}). No significant correlations with amygdyala or additional significant correlations between anterior insula activity and self-report were observed for either genotype subgroup using ROI-based or voxelwise analyses at the above corrected thresholds.

![5-HTTLPR genotype effects on association between anterior insula activation and intolerance of uncertainty in patients.\
Patients with two L~A~ alleles (*n* = 14) and higher scores on the Intolerance of Uncertainty Scale (IUS) had more anterior insula activation across aversive and neutral valences in anticipation of and response to affective pictures in the *a priori* defined anterior insula region of interest (inset). B) A voxelwise regression for patients with two L~A~ alleles indicated a positive association between the IUS and bilateral anterior insula activation (inset) at *p*\<0.05, corrected. No associations with the IUS were observed for patients with at least one S or L~G~ allele (*n* = 36). The association remained significant even after removing the individual with the highest insula activation, *r* = 0.44, *p* = 0.001. Y-axes display mean percent signal change averaged over displayed ROIs/clusters. Solid regression lines indicate all patients, triangular markers and black dashed lines indicate patients with two L~A~ alleles, and circular markers and gray dashed lines indicate patients who are S/L~G~ carriers. Z-values on axial images indicate Tailarach and Tournoux coordinates for the AFNI MNI-152 brain used for normalizing.](pone.0115820.g003){#pone.0115820.g003}

Ethnicity {#sec011}
---------

For each group (patient/non; high/low gene expression), there were no outliers (2 SDs difference) according to ethnic group (African American/Non; Asian/Non; No Ethnicity Reported/Reported) with the exception of one African American control participant with the low SERT expressing genotype who had excessively high amygdala responses. Removing this data point did not alter the within-group or between-group effects reported above.

Discussion {#sec012}
==========

Evidence suggests that genes do not encode for specific psychiatric illnesses or even for specific psychiatric symptoms. However, evidence is mounting that common genetic polymorphisms play important roles in the development of affective disorders, stress reactivity, and responsiveness to treatment \[[@pone.0115820.ref005],[@pone.0115820.ref010],[@pone.0115820.ref015],[@pone.0115820.ref016],[@pone.0115820.ref059]\]. In the present study, the impact of serotonin transporter genotype on affective neural responses distinguished patients with clinical anxiety (GAD; some of whom were also diagnosed with SAD and/or MDD) from healthy non-psychiatric participants. In both the amygdala and anterior insula, patients with two L~A~ alleles exhibited greater activation across anticipatory cue and affective picture presentations than patients who are S/L~G~ carriers. Moreover, the patients showed an association between greater amygdala and insula responses and the number of L~A~ alleles. Finally, the pattern of neural responding in patients correlated with self-reported intolerance of uncertainty, a central feature across multiple affective disorders \[[@pone.0115820.ref045],[@pone.0115820.ref060]\].

The activation patterns found here are consistent with a previous neuroimaging study of 5-HTTLPR genotype and amygdala responding in another mixed patient group including GAD, SAD, separation anxiety disorder, and MDD \[[@pone.0115820.ref011]\] but divergent from a sample reported as MDD but lacking details on psychiatric comorbidity \[[@pone.0115820.ref012]\]. In the first study, patients with the L~A~/L~A~ genotype had greater amygdala activity than S/L~G~ carriers for both fear and happy face presentations in an adolescent sample \[[@pone.0115820.ref011]\]. In the second study, the number of low expressing alleles in MDD patients was associated positively with amygdala response to affective pictures \[[@pone.0115820.ref012]\]. Our results extend these patient data to an adult sample anticipating and then viewing affective pictures, specifying additional clinical characteristics, and also replicating amygdala patterns in the anterior insula. The present study is also one of a growing number of neuoroimaging genetics studies to use the critically important triallelic classification in patient samples \[[@pone.0115820.ref011],[@pone.0115820.ref012],[@pone.0115820.ref013],[@pone.0115820.ref017]\]. Potential mechanisms for 5-HTTLPR genotype effects remain an area of active investigation \[[@pone.0115820.ref015],[@pone.0115820.ref061],[@pone.0115820.ref062]\], but these data add to the growing corpus of literature that suggest greater complexity in how the 5-HTTLPR genotype influences affective neural circuitry, especially in psychiatric disorders. The results suggest that the low expressing 5-HTTLPR variant does not, in all cases, lead to greater responsivity in affective neural systems. A wide range of deleterious as well as protective mood and environmental factors could alter functional trajectories in 5-HTTLPR variant subtypes \[[@pone.0115820.ref005]\] which should be examined further in relation to our findings.

The functional significance of genotype effects warrants careful consideration of specificity and context. Anatomic specificity for the amygdala and insula in the current report was ascertained by evaluating reactivity in other key brain areas implicated in work on emotion and psychopathology. 5-HTTLPR genotype effects were not observed for the ACC, aMCC, or hippocampus. Conversely, there was an absence of predicted specificity with respect to findings for particular components of the fMRI task employed. The pattern of reduced amygdala and insula responses for patients with at least one S or L~G~ allele was observed across the anticipation and picture periods and was equivalent for aversive and neutral trials. Indeed, we did not extend our previous findings of increased anticipatory amygdala activity in GAD patients without other Axis I comorbidities \[[@pone.0115820.ref023]\] to the present group of mostly comorbid GAD patients. Because the previous study did not include DNA collection, we could not ascertain whether genotype differences contributed to the discrepant findings for anticipatory activity. Also of relevance is the recent discussion of statistical power in neuroscience research \[[@pone.0115820.ref063]\] noted above as a potential explanation for not replicating the 5-HTTLPR genotype effect in amygdala activity reported in healthy populations \[[@pone.0115820.ref010]\]. Given a wealth of published work supporting greater affective responsivity in healthy individuals with short alleles, our lack of replication for this effect in our control sample is probably best explained by low statistical power. For future studies, if recruitment begins with assays of genotype before the imaging acquisition, participants can be pre-selected to fill these smaller cells and increase power in detecting neurobiological effects. The pattern in patients, on the other hand, was of a sufficient magnitude to yield statistical significance. Given the strength of the patient findings, it is evident that 5-HTTLPR genotype effects are particularly pronounced in patients but have a different impact on neural response to affective stimuli as compared with weaker effects observed in healthy samples.

To put these findings in context, it is helpful to consider the dynamic interplay of processes that may be involved in the development of affective disorders along with limitations of the present study. Risk for development of clinically significant anxiety and depression involves many genes, complex interactions with life stress, and depends on developmentally dynamic biological processes. Stressful life events may influence physiological reactivity as determined by complex interactions between serotonin transporter genotype and age, type of stressful experience, and number of stressful experiences \[[@pone.0115820.ref061]\]. Genetic contributions to neural responsivity may similarly set the stage for dysregulated affective responding by contributions to an intermediate phenotype the ultimate consequence of which is determined by experiential factors \[[@pone.0115820.ref064],[@pone.0115820.ref065]\]. Amygdala responding to fearful faces is also greater for children thought to be at risk for developing major depression given their family histories, consistent with the intermediate phenotype hypothesis \[[@pone.0115820.ref066]\]. Similarly, healthy participants with elevated anxiety levels ('anxiety prone') show greater levels of amygdala and insula activation to emotional faces \[[@pone.0115820.ref067]\], perhaps as a function of genetic risk but without stressful life event contributions to induce full-blown disorders. Our results do not yield a genetic mechanism for development of affective disorders. Instead, they suggest a specific impact on neurobiology among patients that subdivides this group into hyper or hypo amygdala and insula responsivity and that may resolve apparent differences across studies, especially in GAD \[[@pone.0115820.ref023],[@pone.0115820.ref037]\]. There may be additional experimental paradigms that uncover similar or different results from those found here such as those that rely more on reward processing as being more directly relevant to depression. Having additional participants with single disorders (GAD or MDD or SAD) would also help to test potential differences by diagnostic group. Finally, we did not take histories of stressful life events that would have been informative on the course of illness development and contributions of life events to observed neural group differences which should be a focus of future studies.

Conclusion {#sec013}
----------

Using a triallelic polymorphism (5-HTTLPR and rs25531) to investigate genetic variation in serotonin transporter expression among patients free of medications that might influence serotonin activity in the brain, we establish evidence for the influence of serotonin transporter gene variants on amygdala and anterior insula activity in pathology spanning GAD, SAD, and MDD. Importantly, serotonin transporter expression influences on activity in affective neurocircuitry may diverge in pathological and healthy individuals, as shown here in adults and previously in a mixed sample of adolescent patients \[[@pone.0115820.ref011]\]. Neural profiles that include genetic subtypes could serve as endophenotypic markers of disorders, symptom clusters, or psychopathology dimensions, and inform pioneering efforts in the development of individualized treatment regimens and personalized medicine.

Supporting Information {#sec014}
======================

###### The experimental paradigm.

The experimental paradigm included three types of warning cues (X, O, ?). The 'X' cue indicated that an aversive picture would be presented; the 'O' cue indicated that a neutral picture would be presented; the '?' cue indicated an equal probability of either an aversive or neutral picture. Warning cues were presented for two seconds. Pictures from the International Affective Picture System (IAPS) were presented for one second. Ratings of pictures or mood (50% of each, counterbalanced by picture valence) were presented for 5 seconds following each picture. ISIs between cue and picture ranged from 4--10 seconds, between picture and rating scale varied between 5--9 seconds, and between rating scale and subsequent warning cue ranged between 1--5 seconds. Aversive and neutral pictures were equated for luminance, and men and women viewed slightly different aversive picture sets based on normative ratings (36). Pictures shown below are not from IAPS and are for illustration purposes only. In addition to the 114 cue-picture trials described in the text, there were 14 catch trials for which no picture was presented and 12 catch trials for which a picture was presented with no warning cue (counterbalanced by valence). The fMRI data from these catch trials were not analyzed for this report. On the catch trials without a picture, a rating scale for anticipatory anxiety was presented for 5 s. Using a response box during the fMRI experiment, participants provided mood or picture ratings after the presentation of all pictures on an 11-point rating scale (-5 for "unpleasant," 0 for "neutral," 5 for "pleasant") and anticipatory anxiety ratings after the cues on catch trials without a picture (0 for "Not at all," 4 for "Moderately," 8 for "Extremely"). Approximately one week before the fMRI experimental session, all subjects were positioned in a mock scanner, including head coil, goggles, and response box. After being instructed about all cue-picture pairings, subjects viewed an abbreviated version of the experimental paradigm, using pictures not shown during the experimental session.

(TIF)

###### 

Click here for additional data file.
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